Market Wrap: NEXTDC surges as cash pressure divides the week’s winners

The week’s biggest move came from NEXTDC (ASX:NXT), which rose 77.17%. Goodman Group and Digital Realty sought to buy up to 9.9% of the data-centre operator at $9.50 a share. Investors treated the purchase as a sign that strategic buyers see value after NEXTDC cut its outlook and delayed the M3 Melbourne project. The buyers have not made a takeover offer, so the share price could fall if they stop buying.

Vintage Energy (ASX:VEN) gained 50.00%, although the company’s annual report gave investors little comfort. It reported a $35.6 million loss, lower gas production and a warning from its auditor about its ability to keep operating. The stock later fell 25% from its reopening price. That gap shows how quickly early buying can disappear when investors study the cash position.

Embelton (ASX:EMB) rose 43.03% after proposing to leave the ASX and offer other shareholders $11 a share. The price was well above the recent $8.25 close, giving investors a clear reason to buy. The proposal still needs shareholder approval, and shares could become hard to trade if the company leaves the exchange.

Resources seek a clearer route to production

Mining companies produced many of the week’s important announcements. American West Metals (ASX:AW1) outlined an 11-year Storm copper mine with a US$118.9 million after-tax value and first production targeted for 2030. The plan needs funding, permits and another study. Sunrise Energy Metals (ASX:SRL) approved its Syerston scandium mine, aiming to produce 60 tonnes a year from the second half of 2028. A conditional US$400 million US government debt commitment still needs to become usable funding.

Critical minerals also drew attention. Viridis Mining and Minerals (ASX:VMM) signed a binding offtake deal with Solvay that sets minimum prices and volumes for much of its planned rare-earth output. The agreement gives lenders more confidence, but production is not due until 2028. PMET Resources (ASX:PMT) lifted its caesium resource by 55% and added rubidium and lithium resources. These are resources, not mineable reserves, so more study is needed before their value can be tested.

Cash needs shaped the share-price winners and losers

Several companies raised money to keep projects moving. Avenira (ASX:AEV) secured $48.87 million for the Wonarah phosphate mine and plans its first shipment in the first half of 2027. QMines (ASX:QML) raised $5.5 million for its Mt Chalmers feasibility study. These deals reduce immediate pressure, but new shares dilute existing holders.

Other raises brought a colder response. ADX Energy (ASX:ADX) fell 35.29% after launching a partly underwritten rights issue. It warned that failing to complete the raise would create serious concerns about its ability to continue. Noxopharm (ASX:NOX) fell 28.57% as it sought cash before a lupus trial, while note conversions would create many new shares. The common concern was simple: investors may provide the cash, but they receive a smaller percentage of the company.

Deals and healthcare milestones move forward

Takeover activity continued across the market. Ingenia Communities (ASX:INA) reopened talks with Warburg Pincus after a proposal worth up to $5.60 a security. AVID Property Group has until 10 November to respond. Peet (ASX:PPC) cleared its first Court step before a 7 December shareholder vote. Noumi (ASX:NOU) won strong shareholder support for Arrovest’s takeover, but still needs Court approval.

Healthcare companies reported more direct commercial progress. Pacific Edge (NZX:PEB) gained 25.53% after Medicare confirmed coverage for its bladder tests from 20 December. Neuren Pharmaceuticals (ASX:NEU) lifted 2026 income guidance after strong DAYBUE sales. Radiopharm Theranostics (ASX:RAD) agreed with the US Food and Drug Administration on a single late-stage trial for RAD101, with patient dosing planned for the first half of 2027. In each case, the next test is whether approvals turn into regular sales or trial results.